Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clinical trials. Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown. Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638(N/+) mice. HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine. Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis. Similar effects were observed for HDAC2 and, to a lesser extent, for HDAC1. HDAC3 silencing also selectively induced expression of alkaline phosphatase, a marker of colon cell maturation. Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression. However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors. These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression. These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growth-inhibitory and apoptotic effects induced by HDAC inhibitors are probably mediated through the inhibition of multiple HDACs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, HDAC3 has been suggested to be involved in carcinogenesis by affecting cell differentiation and apoptosis (52).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [52]
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Histones and histone modifications
Peterson, C. L., & Laniel, M.-A. (2004) · Current Biology · doi:10.1016/j.cub.2004.07.007 · Cited by 1,313
Intestinal Epithelial Cell Surface Membrane Glycoprotein Synthesis
Weiser, M. M. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44141-0 · Cited by 1,098
Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression
Laherty, C. D., Yang, W.-M., Sun, J.-M., Davie, J. R., Seto, E., & Eisenman, R. N. (1997) · Cell · doi:10.1016/s0092-8674(00)80215-9 · Cited by 938
Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., Kucherlapati, R., Lipkin, M., Yang, K., & Augenlicht, L. (2002) · Science · doi:10.1126/science.1069094 · Cited by 936
Self-citationLost in Transcription: p21 Repression, Mechanisms, and Consequences
Gartel, A. L., & Radhakrishnan, S. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3995 · Cited by 818
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
Research works printed but not linked: 9
- Mariadason, 1997, Am. J. Physiol., 272, G705
- Heerdt, 1994, Cancer Res., 54, 3288
- Mei, 2004, Int. J. Oncol., 25, 1509
- Fischle, 2001, Biochem. Cell Biol., 79, 337, 10.1139/o01-116 · DOI · Paper page
- Mariadason, 2001, Cancer Res., 61, 3465
- Sowa, 1999, Cancer Res., 59, 4266
- Mariadason, 2003, Cancer Res., 63, 8791
- Yang, 2001, Cancer Res., 61, 565
- Bailey, 1999, Mol. Endocrinol., 13, 1155, 10.1210/mend.13.7.0305 · doi:10.1210/mend.13.7.0305 · Paper page
Cited by
Items 401–500 of 611
Yan, M., Qian, Y.-M., Yue, C.-F., Wang, Z.-F., Wang, B., Zhang, W., Zheng, F.-M., & Liu, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.9922 · Cited by 11
Hofmanová, J., Slavík, J., Ovesná, P., Tylichová, Z., Vondráček, J., Straková, N., Vaculová, A. H., Cigánek, M., Kozubík, A., Knopfová, L., et al. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1196-y · Cited by 12
Acetylation of Endogenous STAT Proteins
Ginter, T., Heinzel, T., & Krämer, O. H. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-242-1_12 · Cited by 13
An Olefin Cross-Metathesis Approach to Depudecin and Stereoisomeric Analogues
Cheng‐Sánchez, I., García‐Ruiz, C., Guerrero‐Vásquez, G. A., & Sarabia, F. (2017) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b00424 · Cited by 10
Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation
Vu, T. K., Thanh, N. T., Minh, N. V., Linh, N. H., Thảo, N. T. P., Nguyen, T. T. B., Hien, D. T., Chinh, L. V., Duc, T. H., Anh, L. D., et al. (2020) · Medicinal Chemistry · doi:10.2174/1573406416666200420081540 · Cited by 10
Xie, Y., Tang, P., Xing, X., Zhao, Y., Cao, S., Liu, S., Lü, X., & Zhong, L. (2020) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2020.118669 · Cited by 10
Hirata, Y., Hirata, M., Kawaratani, Y., Shibano, M., Taniguchi, M., Yasuda, M., Ohmomo, Y., Nagaoka, Y., Baba, K., & Uesato, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.053 · Cited by 10
Ghiaghi, M., Forouzesh, F., & Rahimi, H. (2019) · PubMed Central · Cited by 10
Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma
Mastoraki, A. T., Schizas, D., Charalampakis, N., Naar, L., Ioannidi, M., Tsilimigras, D. I., Sotiropoulou, M. G., Moris, D., Vassiliu, P., & Felekouras, E. S. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00454-x · Cited by 10
The design of a novel near-infrared fluorescent HDAC inhibitor and image of tumor cells
Huang, Y., Ru, H., Bao, B., Yu, J., Li, J. X., Zang, Y., & Lu, W. P. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115639 · Cited by 10
The Roles of Natural Compounds in Epigenetics
Yang, Y., Chi, Z.-H., Gao, R., & Lei, Z. (2018) · Natural Product Communications · doi:10.1177/1934578x1801300835 · Cited by 9
Pharmacodynamic markers for histone deacetylase inhibitor development
Heinzel, T., & Krämer, O. H. (2007) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2008.06.003 · Cited by 13
Narita, N., Fujieda, S., Kimura, Y., Ito, Y., Imoto, Y., Ogi, K., Takahashi, N., Tanaka, T., Tsuzuki, H., Yamada, T., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.089 · Cited by 9
Epigenetic drugs for cancer therapy
Yan, B., Li, X., Johnson, A., Yang, Y., Jian, W., & Qiu, Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-799958-6.00018-4 · Cited by 10
Kee, H. J., Kim, G. R., Lin, M. Q., Choi, S. Y., Ryu, Y., Jin, L., Piao, Z. H., & Jeong, M. H. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.0266 · Cited by 9
Swain, S. D., Grifka‐Walk, H. M., Gripentrog, J. M., Lehmann, M. M., Deuling, B., Jenkins, B., Liss, H., Blaseg, N. A., Bimczok, D., & Kominsky, D. J. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00071.2019 · Cited by 9
“Some well-known pathways involved in butyrate response include STAT1 (27), Wnt (29), and p21 (66).”
BackgroundFluoride Alters Gene Expression via Histone H3K27 Acetylation in Ameloblast-like LS8 Cells
Yamashita, S., Okamoto, M., Mendonca, M., Fujiwara, N., Kitamura, E., Chang, C.-S., Brueckner, S., Shindo, S., Kuriki, N., Cooley, M. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179600 · Cited by 9
“Previous studies demonstrated that inhibition of HDAC2 and HDAC3 increased p21 expression in human colon cancer [37].”
BackgroundZhou, Y., Luo, Q., Gu, L., Tian, X., Zhao, Y., Zhang, Y., & Wang, F. (2025) · Pharmaceuticals · doi:10.3390/ph18040563 · Cited by 13
“For example, HDAC1 is upregulated in breast, prostate, gastric, and colon cancers [35–38]; HDAC2 is found to be overexpressed in cervical, gastric, and colorectal tumors; and HDAC3 has a high expression level in colon carcinomas [38].”
Zhang, Q., & Li, J. (2012) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2012.33.2.535 · Cited by 8
Zhang, S., Wu, S., & Weimin, T. (2016) · Frontiers of Agricultural Science and Engineering · doi:10.15302/j-fase-2016125 · Cited by 9
Venugopal, D., & Dhanasekaran, S. (2020) · Studies in natural products chemistry · doi:10.1016/b978-0-12-819483-6.00007-2 · Cited by 13
Possible Role of Autophagy in the Treatment of Pancreatic Cancer with Histone Deacetylase Inhibitors
Rikiishi, H. (2010) · Cancers · doi:10.3390/cancers2042026 · Cited by 8
“Breast cancer HDAC4, HDAC6 Increase [66] Colon cancer HDAC1, HDAC2, HDAC3, HDAC8 Increase [67] Colorectal cancer HDAC1, HDAC2, HDAC3, SIRT1 Increase [68] Gastric cancer HDAC1, HDAC2, HDAC3 Increase [31] Glioma SIRT2 Decrease [35]”
BackgroundEpigenetics: The master control of endothelial cell fate in cancer
Subramaniam, A. V., Yehya, A. H. S., Cheng, W. K., Wang, X., & Oon, C. E. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116652 · Cited by 8
Histone Deacetylase Inhibitors in Cancer Therapy
Lu, Y., Chen, C., Cheng, A., Sargeant, A. M., & Kulp, S. K. (2008) · CRC Press eBooks · doi:10.1201/9781420045802.ch22 · Cited by 9
Systematic analysis of histone acetylation regulators across human cancers
Song, C., Liu, X. S., Lin, W., Lai, K., Pan, S., Lu, Z., Li, D., Li, N., & Geng, Q. (2023) · BMC Cancer · doi:10.1186/s12885-023-11220-7 · Cited by 8
“HDAC3 has been shown to regulate the biological activities of colon cancer cells, including proliferation, differentiation and apoptosis [31, 32].”
BackgroundJha, T., Jana, R., Banerjee, S., Baidya, S. K., Amin, S. A., Gayen, S., Ghosh, B., & Adhikari, N. (2024) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2024.2350504 · Cited by 7
“HDAC3 overexpression is strongly correlated with cancerous proliferation, and metastasis [3,12,13].”
BackgroundEpigenetic contribution to cancer
Quan, S., & Huang, H. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.05.003 · Cited by 10
HDAC Inhibitors and Other Histone Modifying Natural Products as Emerging Anticancer Agents
Salvador, L. A., & Luesch, H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4654-5_4 · Cited by 8
Epigenetic-based cancer therapeutics: new potential HDAC8 inhibitors
Hassanzadeh, M., Mahernia, S., Caprini, G., Fossati, G., Adib, M., Moakedi, F., & Amanlou, M. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1813203 · Cited by 7
“It has been reported that the HDAC3 gene is overexpressed in human colon cancer and its inhibition leads to growth arrest, colon cell maturation and apoptosis (Wilson et al., 2006).”
BackgroundZafar, S. F., Nagaraju, G. P., & El‐Rayes, B. F. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.691473 · Cited by 8
“Gastric and colorectal cancers have also been shown to overexpress HDAC1 and HDAC3, respectively [45,46].”
BackgroundKim, I. S., Kim, H. S., Kim, M., Kwon, J., Kim, E., Hwang, H., Oh, P., Lim, S. T., Sohn, M., Kim, D. H., et al. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2320 · Cited by 11
Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation
Dewaker, V., Srivastava, P. N., Verma, S. K., Srivastava, A. K., & Prabhakar, Y. S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1989037 · Cited by 7
Critical appraisal of epigenetic regulation of galectins in cancer
Gadwal, A., Modi, A., Khokhar, M., Vishnoi, J. R., Choudhary, R., Elhence, P. A., Banerjee, M., & Purohit, P. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02048-x · Cited by 6
The epigenetic landscape in intestinal stem cells and its deregulation in colorectal cancer
Larue, A., & Atlasi, Y. (2024) · Stem Cells · doi:10.1093/stmcls/sxae027 · Cited by 11
“124-126 Silencing or inhibition of these HDACs result in decreased growth and proliferation and increased apoptosis, 125,127,128 which has led to the development of numerous HDAC inhibitors, currently under preclinical study or early clinical trials in metastatic CRC.”
BackgroundImidazo–benzothiazoles a potent microRNA modulator involved in cell proliferation
Pushpavalli, S. N. C. V. L., Ramaiah, M. J., Lavanya, A., Ganesh, R. A., Kumbhare, R. M., Bhadra, K., Bhadra, U., & Pal‐Bhadra, M. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.058 · Cited by 6
Chen, Y., Huang, W., Hsu, J., Yu, C., Wang, W., & Guh, J. (2013) · The Prostate · doi:10.1002/pros.22641 · Cited by 6
“The compensatory effect on expression levels also has been demonstrated in other studies which demonstrate that the expression of HDAC2 and HDAC3 is induced in HDAC1-deficient cells [26].”
Lallès, J. P., Michel, C., Theodorou, V., & Segain, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801383-0.00017-7 · Cited by 6
An Overview of the Epigenetic Modifications of Gene Expression in Tumorigenesis
Amiri, L. S., Barzegar, A., Rafiei, A., & Amjadi, O. (2019) · Research in Molecular Medicine · doi:10.18502/rmm.v6i3.4606 · Cited by 6
“when compared to expression levels in their normal counter parts (71, 81-83).”
BackgroundZhang, J., Hu, J., Peng, K., Song, W., Zhi, S., Yang, E., Zhao, J., & Hou, H. (2019) · Chemical Communications · doi:10.1039/c9cc05995d · Cited by 6
Dewaker, V., & Prabhakar, Y. S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266250924230920042845 · Cited by 7
Ganai, S. A., Shah, M. D., Dar, S. R., & Padder, S. A. (2024) · The Nucleus · doi:10.1007/s13237-024-00503-4 · Cited by 6
“Like other cancers, dysregulation of epigenetic enzymes also forms the pathophysiological basis of colorectal cancer [8, 54, 128].”
Synthesis and Evaluation of 9-epi-Koshidacin B as Selective Inhibitor of Histone Deacetylase 1
Ghosh, R., Biswas, S., Bagchi, A., & Chattopadhyay, S. K. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00913 · Cited by 6
Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
Garmpis, N., Damaskos, C., Garmpi, A., Valsami, S. I., & Dimitroulis, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00013-9 · Cited by 9
Sardar, S., Jyotisha, Amin, S. A., Khatun, S., Qureshi, I. A., Patil, U. K., Jha, T., & Gayen, S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2227710 · Cited by 5
“A number of studies demonstrate that over and under expression of HDAC1 has major role in promoting of survival and proliferation of colon cell, which lead to colon cancer (Wilson et al., 2006).”
BackgroundRegulation of proliferation, apoptosis and cell cycle in gastrointestinal disorders
Jackson, L. N., & Evers, B. M. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.024 · Cited by 8
Adewole, K. E., & Ishola, A. A. (2020) · Current Drug Discovery Technologies · doi:10.2174/1568009620666200502013657 · Cited by 5
The Impact of Gut Microbiota in Human Health and Diseases: Implication for Therapeutic Potential
Ha, E.-M. (2011) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2011.19.2.155 · Cited by 8
HDAC inhibitors and ionizing radiation: Combinatorial strategy to combat lung cancer
Sarkar, D. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.9.8339 · Cited by 7
PsA inhibits the development of bovine embryos through epigenetic and oxidative stress
Ma, X., Zhan, C., Ma, P., Guo, J., Su, L., Zhang, Y., Jing, Z., Liu, H., Wang, J., & Lu, W. (2023) · American Journal of Veterinary Research · doi:10.2460/ajvr.22.09.0159 · Cited by 6
“15,16 HDACs tighten chromatin structure and repress transcription and gene expression by removing acetyl groups from histone or nonhistone proteins.”
Ng, I., Luk, I. Y., Nightingale, R., Reehorst, C. M., Dávalos-Salas, M., Jenkins, L. J., Fong, C. Y., Williams, D. S., Watt, M. J., Dhillon, A. S., et al. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00160.2023 · Cited by 4
Self-citationPeng, Y., Gao, Q., Wang, Y., Yao, Q., & Zhang, J. (2021) · ChemMedChem · doi:10.1002/cmdc.202001004 · Cited by 4
Evolution of Epigenome as the Blueprint for Carcinogenesis
Farooq, Z., Shah, A. T., Tauseef, M., Rather, R. A., & Anwar, M. (2021) · Biochemistry · doi:10.5772/intechopen.97379 · Cited by 4
Arakelyan, J., Rusanov, D. A., Chang, M. R., Asaturova, A. V., Kireeva, G. S., Alshehri, M. M., Ang, W. H., & Babak, M. V. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214899 · Cited by 5
Zang, X., Peraro, L., Davison, R. T., Blum, T. R., Vallabhaneni, D., Fennell, C. E., Cramer, S. L., Shah, H., Wholly, D. M., Fink, E. A., et al. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c00854 · Cited by 4
Role of HDACs and DNMTs in cancer therapy: A review
Walia, Y. K., & Sharma, V. K. (2013) · Cited by 4
The Epigenetic Targets of Berry Anthocyanins in Cancer Prevention
El-Ella, D. M. A., & Bishayee, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812494-9.00006-8 · Cited by 5
Ganai, S. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8179-3_4 · Cited by 4
MEMS-based near-infrared spectroscopy with AI for real-time breast cancer margin assessment
Ibrahim, H. M., Aref, M. H., Elhadad, M. K., Hussein, A. A., Sharawi, A. A., & Saleh, N. (2026) · Surgical Oncology · doi:10.1016/j.suronc.2026.102395 · Cited by 3
Chen, C., Wang, K., Zhang, Y., Qi, Y., Shen, C., Zhang, Z., Zhang, Z., Yang, H., & Hu, H. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00518-1 · Cited by 3
“Moreover, research results have shown that HDAC3 exhibits high expression in STAD, PAD, and READ [60], and the overexpression of HDAC1 and 2 in READ is associated with poor prognosis [61, 62].”
BackgroundAhmad, S., Schaduangrat, N., Meewan, I., & Shoombuatong, W. (2025) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbbio.2025.3602433 · Cited by 3
“This enzyme plays a pivotal role in diverse biological processes, including inflammatory responses, cognitive function, and metabolic regulation, with particular implications for memory formation and diabetic pathogenesis [15], [16].”
Dynamic Regulation of Adherens Junctions: Implication in Cell Differentiation and Tumor Development
Pelissier-Rota, M. A., Chartier, N. T., & Jacquier‐Sarlin, M. R. (2015) · Springer eBooks · doi:10.1007/978-94-017-7380-5_4 · Cited by 3
Lu, H., Jin, X., Jin, Y., Huang, B., Wang, C., Wang, C., Ma, F., Chen, Y., Li, J., Cong, Y., et al. (2016) · Chemical Research in Chinese Universities · doi:10.1007/s40242-016-6105-7 · Cited by 3
Ooizumi, Y., Kojima, K., Igarashi, K., Tanaka, Y., Harada, H., Yokota, K., Kaida, T., Ishii, S., Tanaka, T., Yokoi, K., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07795-w · Cited by 3
Molecular Targets of Anticancer Agents from Filamentous Marine Cyanobacteria
Tan, L. T., & Gupta, D. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-07145-9_27 · Cited by 4
“It has been observed that the over expression of class I HDAC enzymes, such as HDAC1 and HDAC3, occurs in colon and prostate tumors, respectively [77, 78].”
BackgroundDNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer
Qiu, Y., Shabashvili, D., Li, X., Kumari, P., Chen, M., & Zajac‐Kaye, M. (2012) · InTech eBooks · doi:10.5772/35977 · Cited by 4
“HDAC3 forms a stable complex with nuclear receptor corepressor (N-CoR) and silencing mediator of retinoic and thyroid receptors (SMRT) (Wen et al., 2000,Guenther et al., 2001,Guenther et al., 2000).”
BackgroundInfluentialZinc and Zinc-Dependent Proteins in Cancer and Chemotherapeutics
Guynn, J. M., & Chan, E. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-55448-8_4 · Cited by 4
Karlic, H., & Varga, F. (2009) · Epigenetics and human health · doi:10.1002/9783527628384.ch15 · Cited by 3
Herp, D., Ridinger, J., Robaa, D., Shinsky, S. A., Schmidtkunz, K., Yesiloglu, T. Z., Bayer, T., Sehr, P. A., Gunkel, N., Miller, A. K., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12440096.v3 · Cited by 2
Commensal microbiota-derived signals regulate host immune system through epigenetic modifications
Takahashi, D., & Hase, K. (2015) · Inflammation and Regeneration · doi:10.2492/inflammregen.35.129 · Cited by 3
Histone Deacetylases in the Process of Halisarca dujardini Cell Reaggregation
Кравчук, О. И., Burakov, A. V., Горностаев, Н. Г., Mikhailov, K. V., Adameyko, K. I., Finoshin, A. D., Georgiev, A., Mikhailov, V. S., Ерюкова, Ю. Э., Rubinovsky, G. A., et al. (2021) · Russian Journal of Developmental Biology · doi:10.1134/s1062360421050052 · Cited by 2
How Histone Deacetylase 3 Controls Hepcidin Expression and Hepatitis C Virus Replication
Shcherbakova, A. S., Kochetkov, S. N., & Kozlov, M. V. (2023) · Molecular Biology · doi:10.31857/s0026898423030096 · Cited by 3
Vitamin D and the epigenome: basic definitions, mechanisms and clinical effects
Хавкин, А. И., Лошкова, Е. В., Владимирович, Д. И., Kondratyeva, E., & Erokhina, M. I. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-217-9-209-221 · Cited by 2
Negative regulation of HDAC3 transcription by histone acetyltransferase TIP60 in colon cancer
Lee, S., Park, J., & Seo, S. (2024) · Genes & Genomics · doi:10.1007/s13258-024-01524-8 · Cited by 2
“HDAC3 influences cell differentiation, apoptosis, cancer progression, and the cell cycle (Adhikari et al. 2018; Li et al. 2014; Wilson et al. 2006).”
Ambroxol induces myeloma cell death by inhibiting autophagy
Hattori, Y., Sugiyama, H., Miyashita, Y., Shibata, S., Okaue, T., Matsumoto, Y., Yamada, T., Yamamoto, T., Yamaguchi, T., Yamazaki, K., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100100 · Cited by 4
“40 HDAC inhibition by panobinostat was also thought to cause these gastrointestinal toxicities.”
Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
de Andrade, P. V., Andrade, A. F., Queiróz, R. G. D. P., Trevisan, F. A., Tone, L. G., & Valera, E. T. (2014) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524914666141112093541 · Cited by 2
“In pediatric brain tumors, HDACs 1, 2, and 3 have been reported to be over expressed in cancer cells originated from different tissues [20-22].”
BackgroundGenetic variants in apoptosis‐related genes associated with colorectal hyperplasia
Gerola, S., Nittka, S., Kähler, G. F. B. A., Tao, S., Brenner, H., Binelli, G., Eils, R., Brors, B., & Neumaier, M. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22185 · Cited by 3
“Overexpression of Class I HDACs also causes a reduction in apoptosis (de Ruijter et al., 2003; Wilson et al., 2006).”
BackgroundEpigenetic and Signaling Pathway Regulation in Hair Cell Regeneration
Li, H. (2015) · Cellular & Molecular Medicine Open access · doi:10.21767/2573-5365.100006 · Cited by 5
Olguín-Reyes, S. D. R., Hernández-Ojeda, S. L., Govezensky, T., Camacho‐Carranza, R., & Espinosa-Aguirre, J. J. (2018) · Biomedical Research - India · doi:10.4066/biomedicalresearch.29-18-342 · Cited by 1
“Antibodies against CYP1B1, DNMT1, DNMT3a, HDAC1, HDAC2, HDAC3 and HDAC4 were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).”
BackgroundInfluentialHow Histone Deacetylase 3 Controls Hepcidin Expression and Hepatitis C Virus Replication
Shcherbakova, A. S., Kochetkov, S. N., & Kozlov, M. V. (2023) · Molecular Biology · doi:10.1134/s0026893323030081 · Cited by 2
“Knockdown of NCoR1 and HDAC3 separately increased hepcidin expression, whereas simultaneous knockdown of both genes had a synergistic effect [41].”
BackgroundGanai, S. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8179-3_5 · Cited by 2
Chromatin Remodeling in Carcinoma Cells
Becker, T. M. (2012) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.201100031 · Cited by 2
Epigenetic Mechanisms in Cancer Formation and Progression
Fratta, E., Sigalotti, L., Covre, A., Parisi, G., Danielli, R., Nicolay, H. J. M., Coral, S., & Maio, M. (2011) · Wiley eBooks · doi:10.1002/9781118005743.ch10 · Cited by 3
Nutrients, Histone Modifications, And Chromatin Remodeling In Chronic Inflammation
Delage, B., & Dashwood, R. H. (2009) · CRC Press eBooks · doi:10.1201/9781420063561.ch6 · Cited by 2
Niknam, M., Varedi, M., Zamani, M., Mokarram, P., & Naghibalhossaini, F. (2023) · Pharmaceutical Sciences · doi:10.34172/ps.2023.19 · Cited by 1
“10,34,44 HDACs are frequently dysregulated in CRC and both the upregulation and loss of expression have been reported.”
BackgroundGürbüz, V. (2025) · Developments and Experiments in Health and Medicine · doi:10.18614/dehm.1751132 · Cited by 1
Shukla, D., Matore, B. W., Murmu, A., Gawande, P., Roy, P. P., & Singh, J. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2605010 · Cited by 2
Epigenetics and One-Carbon Metabolism in Cancer: Mechanisms and Therapeutic Implications
Serpa, J., & Costa, J. R. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_9 · Cited by 2
From bench to bedside: Targeting epigenetics for cancer therapy
Li, G., & Fang, J. (2011) · Clinical Oncology and Cancer Research · doi:10.1007/s11805-011-0580-x · Cited by 1
Targeting Epigenetic Modifiers for Cancer Treatments
Chee, C. S., & Leung, D. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0130-9 · Cited by 1
Epigenetic Biomarkers and Their Therapeutic Applications in Colorectal Cancer
Hartley, A.-V., Martin, M., & Lu, T. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82572 · Cited by 2
“For example, knockdown of HDAC1, 2, and 3 reduced the growth of several CRC cells by largely unknown mechanisms [122].”
BackgroundHistone Deacetylase Inhibitors As Potential Therapeutic Agents For Various Disorders
Thapa, K., Kumar, S., Sharma, A., Arora, S., Grewal, A. K., & Singh, T. G. (2017) · Journal of Pharmaceutical Technology Research and Management · doi:10.15415/jptrm.2017.52014 · Cited by 2
Nesa, E. U., Chen, X., Wang, C., Chen, X., Wang, Y., Qu, Y., Mi, S., Guan, S., Xiao, F., & Cheng, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.01.32 · Cited by 2
“HDAC8 highly expressed that deregulates tumor suppressor gene CDKN2A and causes the progression of the disease (49).”
BackgroundRetractedMansour, M. A., Abbas, S. H., AboulMagd, A. M., Abdel-Rahman, H. M., & Osman, M. S. A. (2023) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2023.234736.1203 · Cited by 5
“Consequently, these substrates have garnered considerable attention as promising targets for cancer therapeutics[154-156].”
BackgroundAcetylation of Histones in Chromatin and Its Functions in Gene Transcription
Shin, K.-J., Lee, D., & Kim, A. (2024) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2024.30.4.199 · Cited by 1
Vitamin D in Obesity and Cancer Prevention
Boughanem, H., Bandera-Merchán, B., & Macías‐González, M. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016506-00027 · Cited by 1
PERSPECTIVES OF THE USE OF SULFORAPHANE IN ANIMAL MODEL OF COLORECTAL CARCINOGENESIS IN BRAZIL
Sobrinho, C. A., Santiago, E. M. D. L., Neves, M. B., Gonçalves, A. D. F., Ramos, E. M., Aydos, R. D., & Ramalho, R. T. (2019) · International Journal for Innovation Education and Research · doi:10.31686/ijier.vol7.iss12.2088 · Cited by 1
“Because Sulforaphane, through activation of Nrf2, increases the activity of phase II enzymes such as glutathione S transferase (GST)[14,20-22,32], which is involved in the elimination of xenobiotic compounds[22,33].”
BackgroundInfluentialMegnassan, E., Fofana, I., Dali, B., Mansilla-Koblavi, F., Frecer, V., & Miertuš, S. (2021) · SDRP Journal of Computational Chemistry & Molecular Modelling · doi:10.25177/jccmm.5.1.ra.10708 · Cited by 1
“Indeed, it has been shown that the breakdown of balance between acetylation and deacetylation levels of chromatin is involved in the acquisition of malignant phenotype [3] Overexpression of histones deacetylases (HDACs) induces low level of histone acetylation leading to silenced regulatory genes and in turn to human…”
BackgroundRen, X., Jiang, Z., & Xu, K. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1948766 · Cited by 1
“[9, 10] investigators found that SMAR1-related proteins in breast cancer are associated with HDAC2 by recruitment of HDAC2 Sin3 and retinoblastoma pocket proteins and inhibited the effects of cyclinD1 on cell cycle aspects by deacetylating the upstream region of cyclinD1 promoter on cyclin and found that the mechanism…”
BackgroundRetractedAnalyzing Lymphoma Development and Progression Using HDACi in Mouse Models
Piskor, E.-M., Winkler, R., & Kosan, C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2788-4_1 · Cited by 1
Pourian, A. (2011) · doi:10.17077/etd.zlkxj5k2 · Cited by 1
Metadata
- Authors
- Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Kyoto Prefectural University of Medicine (JP)
- Vall d'Hebron Institut de Recerca (ES)
- Corresponding author
- Mariadason, John M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 281
- Issue
- 19
- Pages
- 13548-13558
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2105095164
- Semantic Scholar
- c2db47db00c10ecf03aae7c6c6f1c3b194c81502
- Cited by
- 575
- References
- 43
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 31 · 2023: 28 · 2022: 25 · 2021: 18 · 2020: 30 · 2019: 26 · 2018: 27 · 2017: 30 · 2016: 30 · 2015: 38 · 2014: 32 · 2013: 40 · 2012: 28
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5273 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088104, R01CA100823, CA88104-04, CA100823-03)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- HDAC3, class I HDACs, colon cancer, histone deacetylase inhibitors, apoptosis, alkaline phosphatase, duodenal adenoma, crypt cells, gene silencing, tumor suppressor
- MeSH terms
- Cell Differentiation, Colon, Colonic Neoplasms, Histone Deacetylases, Humans, Time Factors, Down-Regulation, Up-Regulation, Gene Expression Regulation, Enzymologic, Apoptosis, Caco-2 Cells, Gene Silencing, HCT116 Cells, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p21, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.